Sort publications on year
-
Pharmaco-Economics
CoĂ»t de la prise en charge des frottis anormaux et des nĂ©oplasies intraĂ©pithĂ©liales du col de l’utĂ©rus en France
BERGERON C, COHET C, BOUEE S, LORANS C, REMY V
BEH ; (1):4-6
-
Pharmaco-Economics
Cost Consequences of Adjuvant Capecitabine, Mayo Clinic and de Gramont Regimens for Stage III Colon Cancer in the French Setting
DOUILLARD JY, TILLEUL P,YCHOU M, DUFOUR P, PERROCHEAU G, SEITZ JF, MAES P, LAFUMA A, HUSSEINI F
Oncology ; 72:248-254
-
Pharmaco-Economics
Cervical cancer screening and associated treatment costs in France
BERGERON C, BREUGELMANS JG, BOUEE S, LORANS C, BENARD S, REMY V
Gynécol Obstét Fertil ; 34:1036-1042
-
Public Health and Epidemiology
Le dépistage du cancer du sein en France : bilan et limites
PHILIP T, KASPARIAN C, FAGNANI F,MOATTI JP, MEUNIER A
Bull. Acad. Natle MĂ©d. ; 189(2):321-339
-
Public Health and Epidemiology
Breast cancer screening in France
PHILIP T, KASPARIAN C, FAGNANI F, MOATTI JP, MEUNIER A
Bull Acad Natl Med ; 189(2):321-336
-
Pharmaco-Economics
Cost-effectiveness of interferon-α2 as adjuvant therapy in malignant melanoma
LAFUMA A, Grob JJ
Expert Opin Pharmacother ; 4(3):343-349
-
Pharmaco-Economics
A simulation model for evaluating the medical and economic outcomes of screening strategies for colorectal cancer
LEJEUNE C, ARVEUX P, DANCOURT V, FAGNANI F, BONITHON -KOPP C, FAIVRE J
Eur J Cancer Prev ; 12(1): 77-84
-
Public Health and Epidemiology
IntĂ©rĂȘt et limites du systĂšme d’information du rĂ©gime AMPI dans le suivi des campagnes de dĂ©pistage des cancers du sein
GADENNE S, HIRTZLIN I, BLUM-BOISGARD C, DACHICOURT PH, SEIGLE O
Journal d'Economie MĂ©dicale ; 20(7-8):417-426
-
Pharmaco-Economics
Economic analysis of adjuvant therapy with interferon alfa 2a in stage II malignant melanoma
LAFUMA A, DRENO B, DELAUNAY M, EMERY C, FAGNANI F, HIEKE K, BONERANDI JJ, GROB JJ
Eur J Cancer ; 37(3):369-375
-
Biometry and database analysis
Management and cost analysis of cancer patients treated with G-CSF: a cohort study based on the French national healthcare insurance database
TILLEUL P, JACOT W, EMERY C, LAFUMA A, GOURMELEN J
J Med Economics ; 2017;20(12):1261-1267
-
Public Health and Epidemiology
Analyser des parcours de sante de patients pour Ă©valuer lâapport de 10 ans de politique de lutte contre le cancer.
DUBURCQ A, COUROUVE L, BETTINGER J, GRANDJEAN H.
Rev Epidemiol Sante Publique ; 2016;64S : S215-S260
-
Public Health and Epidemiology
Etats des lieux et recommandations pour le dĂ©pistage du cancer du col de l’utĂ©rus en France SynthĂšse et recommandations – juillet 2010
HAS
SynthĂšse et Recommandations HAS ; 2010
-
Public Health and Epidemiology
Public health impact of human papillomavirus vaccination on prevention of cervical cancer in France
EL HASNAOUI A, DEMARTEAU N, GRANADOS D, STANDAERT B, DETOURNAY B
Int J Public Health ; 2012;57(1):149-58
-
Pharmaco - Epidemiology
Projection de l’incidence du cancer du sein en 2018 en France
BOUEE S, GROSCLAUDE P, ALFONSI A, FLORENTIN V, CLAVEL-CHAPELON F, FAGNANI F
Bulletin du Cancer ; 2010;97(3):293-299
-
Pharmaco-Economics
Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study
ARMOIRY X, FAGNANI F, BENBOUBKER L, FACON T, FERMAND JP, HULIN C, MOREAU P, AULAGNER G
J Clin Pharm Ther ; 2011;36(1):19-26